lemzoparlimab + azacitidine + venetoclax

**lemzoparlimab + azacitidine + venetoclax** is an investigational combination therapy being studied primarily for the treatment of acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) in adults, especially those not eligible for intensive induction chemotherapy[1][4][6]. This regimen combines three agents: - **lemzoparlimab**: a novel monoclonal antibody targeting CD47, engineered to spare red blood cells while blocking the CD47/SIRPα signaling pathway. By disrupting the "don't eat me" signal of CD47 on tumor cells, it promotes macrophage-mediated phagocytosis of cancer cells[2][3][7]. - **azacitidine**: a hypomethylating agent and cytidine nucleoside analog that inhibits DNA methyltransferase, leading to cytotoxicity and apoptosis in abnormal hematopoietic cells. It is commonly used for MDS and AML. - **venetoclax**: a selective small-molecule inhibitor of BCL-2, which induces apoptosis in malignant cells dependent on BCL-2 for survival. The combination aims to enhance anti-leukemic effects via complementary mechanisms: immunologic activation (lemzoparlimab), epigenetic modulation (azacitidine), and apoptosis induction (venetoclax)[1][6].

Other names

lemzoparlimab + azacitidine + venetoclax